Showing results (301-310 of 396) with videos related to
Sort By:
Pageof 40
The New England Journal of Medicine|April 28, 2025
Zongertinib in Previously Treated <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al.Frontiers in Immunology|March 25, 2021
Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer PatientsClaire Germain, Priyanka Devi-Marulkar, Samantha Knockaert, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2017
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClémence Basse, Sébastien Thureau, Suzanna Bota, et al.The Lancet. Oncology|September 4, 2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trialJordi Remon, Paolo Bironzo, Nicolas Girard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.Clinical Lung Cancer|March 19, 2021
RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical ResectionC Basse, A Botticella, T J Molina, et al.Targeted Oncology|October 18, 2021
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and OutcomesChristos Chouaid, Thomas Filleron, Didier Debieuvre, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC PatientsGiorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, et al.Diagnosis (Berlin, Germany)|August 1, 2024
Bridging the divide: addressing discrepancies between clinical guidelines, policy guidelines, and biomarker utilizationDenis Horgan, Paul Hofman, Reinhard Buttner, et al.European Journal of Cancer (Oxford, England : 1990)|December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC networkArthur Petat, Eric Dansin, Fabien Calcagno, et al.Pageof 40